NCT00643097View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

January 31, 2012

Study Completion Date

November 30, 2016

Conditions
Malignant Neoplasms of Brain
Interventions
BIOLOGICAL

PEP-3 vaccine

Given intradermally

BIOLOGICAL

sargramostim

Given intradermally

DRUG

Temozolomide

Standard of care chemotherapy

Trial Locations (2)

27710

Duke University Medical Center, Durham

77030-4009

M. D. Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

John Sampson

OTHER

NCT00643097 - Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter